Schedule a Meeting
Download Brochure
Table of Content
April 2025
Principal Consultant
Reviewed By
The global hormonal replacement therapy market size is calculated at US$ 24.26 in 2024, grew to US$ 25.88 billion in 2025, and is projected to reach around US$ 46.32 billion by 2034. The market is expanding at a CAGR of 6.68% between 2025 and 2034. Different types of hormones are used in different types of conditions, due to which the demand and production of various hormones are growing, and the hormonal replacement therapy market is growing.
For the treatment of menopausal symptoms, including hot flashes and night sweats, physicians may prescribe hormone replacement therapy (HRT). It helps keep progesterone and estrogen levels in check. Hot flashes, osteoporosis risks, and other menopausal symptoms have all decreased as a result of the widespread use of hormone replacement therapy throughout the years to address illnesses related to menopause in women. Additionally, because of the development of additional hormone-related illnesses targeted at different age groups that impact both men and women, these therapies are driving the market's expansion.
Therefore, it is anticipated that conditions, including growth deficiencies, thyroid issues, and others, would also accelerate the expansion of the worldwide market throughout the course of the projection period. Furthermore, growing knowledge of the contemporary treatment of estrogen and combination therapy may be expanding the market for these goods due to the growth in the prevalence of menopausal diseases in emerging nations.
By supporting medical professionals, researchers, and patients in a variety of ways, artificial intelligence (AI) can significantly contribute to the diagnosis and treatment of menopause. I can predict the onset of menopause and its associated symptoms using data from wearable technology, electronic health records, and patient reports. This can assist medical professionals in planning and providing women who are approaching or going through menopause with more individualized treatment. AI systems can evaluate research and patient data to provide personalized therapy recommendations for menopausal symptoms. These suggestions may involve alternative medicines, hormone replacement treatment (HRT), or lifestyle modifications.
Rising Cases of Hormonal Disorders
Adoption of these treatments has increased worldwide as a result of the rise in the occurrence of adult hormone deficiencies. Additionally, the global increase in menopause disorders and growth deficiencies due to diabetes insipidus is driving the creation of new goods by directing manufacturers' attention toward additional R&D projects. As a result, high prevalence is driving the adoption of new products and effective launch tactics for product portfolio development, which will accelerate the growth of the hormonal replacement therapy market throughout the projection period.
Side Effects due to Hormonal Replacement Therapies
Certain hormone treatments can cause osteoporosis or bone weakening. This makes bones more brittle and, in certain cases, more likely to shatter or fracture. Several hormone therapies increase the risk for a number of health problems. Blood clots, heart attacks, strokes, and cataracts are a few examples. They could potentially increase the risk of uterine cancer.
Bioidentical Hormones Demand
The increasing demand for bioidentical hormones—hormones that are physically identical to those that the human body naturally produces—is one of the most attractive prospects in the hormonal replacement therapy market. Compared to conventional synthetic hormones, these hormones are considered safer and have fewer adverse effects. Furthermore, the emergence of personalized medicine presents an opportunity to tailor hormone treatments to each individual's unique genetic composition, lifestyle, and hormonal needs. Healthcare professionals can enhance the efficacy and safety of therapy by personalizing HRT treatments, which may appeal to patients who are reluctant to use traditional HRT medications. It is anticipated that this trend toward bioidentical and customized hormone treatments will spur market expansion and innovation.
By product, the estrogen and progesterone replacement therapy segment led the hormonal replacement therapy market in 2024. Synthetic estrogen and progestogen are administered as part of hormone treatment (HT) to replenish a woman's declining hormone levels and so reduce menopausal symptoms. Different types of estrogen exist. The hormone is also available as a vaginal ring, gel, or spray. However, the most common forms are the daily tablet and patch. Compared to taking estrogen alone, using progesterone together with estrogen reduces the risk of endometrial (uterine lining) cancer. Progesterone is typically used as a birth control method, but it can also aid with certain menopausal symptoms.
By product, the parathyroid hormone replacement therapy segment is estimated to be the fastest-growing in the hormonal replacement therapy market during the forecast period. The use of PTH(1–84) replacement treatment for hypoparathyroidism shows promise, but further long-term data collection is required. Some nations provide parathyroid hormone (PTH) replacement treatment (1–84). People with some forms of hypoparathyroidism who have low blood calcium levels are treated with parathyroid hormone injections in addition to calcium and vitamin D. Parathyroid hormone replacement treatment must be taken consistently because it only enhances health and does not treat parathyroid disease.
By route of administration, the oral segment held the largest share of the hormonal replacement therapy market in 2024. The therapeutic value of medications and whether patients experience negative side effects are somewhat influenced by how they are administered. In contemporary medicine, the most used method of medication delivery is oral administration. Due to its ease of use, non-invasiveness, and patient compliance, it is often preferred. For the treatment or prevention of CC, several medications previously discussed are administered orally. Compared to alternative administration methods, such as injection, oral administration may be simpler and less uncomfortable.
By route of administration, the parenteral segment is expected to grow at a significant rate in the hormonal replacement therapy market during the forecast period. Sometimes, especially in emergency settings, parenteral administration is chosen over other medication delivery methods. Bypassing the digestive system, the parenteral route of administration delivers medications and nutrients straight into the body. Patients who are unable to take their drugs orally because of severe pain, nausea, vomiting, or unconsciousness must utilize this approach. Parenteral administration is becoming more and more popular in community care and in hospital settings. The most popular and feasible parenteral administration technique is intravenous (IV) administration. It enables prompt therapeutic effects and quick medication administration.
By disease type, the menopause segment was dominant in the hormonal replacement therapy market in 2024. The most common prescription medication used to treat menopausal symptoms, including hot flashes and genitourinary syndrome of menopause (GSM), which includes postmenopausal vaginal dryness, is hormone replacement therapy. In its most basic form, hormone therapy replenishes the female hormones lost during the menopausal transition, namely estrogen and progestogens. There is FDA approval for hormone treatment. For the first ten years following the start of menopause or for the majority of women in their 50s, MHT is safe to use.
By disease type, the hypoparathyroidism segment is estimated to grow significantly in the hormonal replacement therapy market during the forecast period. An uncommon condition known as hypoparathyroidism is typified by low levels of parathyroid hormone (PTH) in the bloodstream and hypocalcemia. After having a thyroidectomy, around 18% of people get hypoparathyroidism, with 9.5% of those patients developing symptoms. The chance of getting hypoparathyroidism rises with age, particularly for people over 50 who have had a complete thyroidectomy. Patients with hypoparathyroidism may benefit from PTH replacement medication. The only endocrine condition in the US for which there isn't a single hormone replacement medication is hypoparathyroidism.
North America dominated the hormonal replacement therapy market share by 40% in 2024 because menopause and growth hormone deficiency problems are becoming more common, and patients aged 35 and older are well aware of the therapy. In addition, the region's growth is being aided by the growing number of regulatory approvals, the introduction of different medicines, the availability of cutting-edge products in the area, and strong healthcare spending.
The largest market for hormone replacement treatment is the U.S., where people over 35 are increasingly using it. Market expansion is driven by the availability of stronger medications and a rise in the target demographic. Other contributing reasons include the increase in the availability of generic hormone replacement treatment medications and developments in drug delivery systems. According to the NIH, about 50% of US women who have gone through menopause have utilized hormone replacement therapy. Every year, 1.3 million women in America go through menopause.
The Menopause Foundation of Canada (MFC) is calling on employers to better support women in this stage of life as World Menopause Month begins. Unmanaged menopausal symptoms are negatively impacting Canadian women's income and productivity at work. Five million women, or one-fourth of Canada's workforce, are over 40; two million are in the 45–55 age range, which is when the majority of women enter menopause. Prominent companies like Sun Life, Arthritis Society Canada, PwC Canada, L'Oréal Canada, and BMO are setting the standard by demonstrating how even minor changes to become menopause inclusive have a significant impact on women's employment.
Asia Pacific is estimated to host the fastest-growing hormonal replacement therapy market during the forecast period. As a result of aging populations, more women are going through menopause in nations like China, India, and Japan. This creates a growing need for efficient ways to manage symptoms, including mood swings, hot flashes, and night sweats. In order to promote the use of HRT, the cultural environment is also employing a tool of its own. With many Asian cultures supplementing their traditional beliefs with contemporary medicine, more and more women are looking for modern answers for their health and well-being and are growing increasingly accepting of hormone replacement therapy and other medical procedures.
Over the next ten years, China's largest demographic group—roughly 300 million people—will be between the ages of 50 and 60. This is comparable to nearly the whole U.S. population. Menopausal women are becoming more prevalent as the population ages. By 2030, there will be over 280 million menopausal women in China, up from the present 230 million.
Population changes that are changing India's social environment highlight the importance of this commemoration. The Technical Group on Population Projections Report (July 2020) projects that by 2031, India's senior population will number 193.4 million. This sharp rise from the 103.8 million elderly people counted in the 2011 Census—roughly 8.6% of the population at the time—highlights how urgent it is to address concerns about healthcare, financial stability, and social inclusion for senior individuals. In India, almost 130 million women are said to be going through or about to go through menopause. Menopause typically strikes Indian women at the age of 46.2.
Europe is expected to grow significantly in the hormonal replacement therapy market during the forecast period. Growing knowledge among women, particularly those going through menopause, has led to a very high demand for hormone replacement therapy (HRT) to control the symptoms of mood swings, hot flashes, and night sweats. In nations like Germany, France, and the UK, as the population ages, an increasing proportion of women are simply looking for effective ways to deal with hormonal chaos every year. Patients in Europe have reason to believe that hormone replacement therapy is safe and effective because of a patient-friendly regulatory environment and a favorable EMA assessment. More demand has been sparked by educational initiatives planned by organizations like the British Menopause Society.
In Germany, nine million women experience menopause, a serious illness that is rarely recognized and much less talked about. In an attempt to win over more women voters, lawmakers take up the subject a year prior to the main election. This is the goal of a new proposal from the center-right CDU/CSU coalition in Germany. Menopause should be given more consideration in medical research and business health management strategies, according to the strategy. This makes menopause a more significant topic for younger women, men, and boys, as well as the economy, rather than merely something that women must endure.
More women are actively looking for help as a result of greater awareness of the menopause. There are very few companies where employees do not experience menopause since over four million women between the ages of 45 and 55 are employed in the UK, and women over 50 make up a significant and increasing portion of the workforce. The UK government believes that promoting the recruitment and retention of older women in the workforce requires a focus on women's health, including menopause.
In April 2024, following the closing of a $60 million Series B investment round led by Emerson Collective, Midi Health announced that it had secured a total of $100 million in funding to date. According to Fern Mandelbaum, Collective Manager Partner, Emerson Collective, women's healthcare has historically been ignored, with substantial unmet requirements during perimenopause and menopause. By offering comprehensive insurance coverage alongside professional, compassionate care, Midi is closing this disparity and ensuring that all women receive the assistance they need and are entitled to.
By Product
By Route of Administration
By Disease Type
By Region
April 2025
April 2025
April 2025
March 2025